Obesity Drug – Talk Bio

Actionable Insights Powered by AI

Kailera Raises $600 Million to Launch Global Phase III Program for Obesity Drug

16 hours ago talkbio0Tagged Bain Capital, clinical pipeline, Funding, GLP-1/GIP Dual Agonist, Kailera, Obesity Drug, Phase 3 Clinical Trials, Series B financing, weight loss therapy

Kailera; obesity drug; Phase III clinical trial; KAI-9531; GLP-1/GIP dual agonist; Series B financing; Bain Capital; weight loss therapy; clinical pipeline; biotech funding